Redx Pharma plc Redx to present new scientific data at ESMO 2017

TIDMREDX

Redx Pharma plc

31 August 2017

31 August 2017

REDX PHARMA PLC (in administration)

("Redx" or "the Company")

Redx to present new scientific data at ESMO 2017

Redx Pharma will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.

 
Session Date & Time          September 9, 2017, 13:15 AM -14:15 GMT+1h 
Session Title               GASTROINTESTINAL TUMOURS, COLORECTAL 
Presentation Title          Identification of an RNF43 mutated gastric cancer patient population with potential 
                            sensitivity 
                            to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay 
                            for patient screening 
Session Location            Hall 8 
Abstract #                  692P 
First author                Matilda Bingham 
 
  Abstract online             https://cslide.ctimeetingtech.com/library/esmo/browse/search/2iw4#2Bb5o02mE 
 

Iain Ross, Chairman, commented:

'We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'

For further information, please contact:

 
Redx Pharma Plc (in administration) 
 
  Contact for the Joint Administrators:    T: + 44 203 
  Chris French                             005 4000 
  James Rossiter 
 
  Cantor Fitzgerald Europe (Nomad &        T: +44 20 
  Broker)                                  7894 7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)           T: +44 20 
                                          3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
 

About Redx Pharma Plc (in administration)

Company website: redxpharma.com

Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASDWSWFFWSEIA

(END) Dow Jones Newswires

August 31, 2017 04:00 ET (08:00 GMT)